Related Experiment Videos
Triazolam in patients with obstructive sleep apnea
1Department of Medicine, Long Beach Veterans Administration Medical Center, CA 90822.
American Journal of Respiratory and Critical Care Medicine
|February 1, 1995
Summary
Triazolam (0.25 mg) slightly prolonged apnea duration and increased desaturation in severe obstructive sleep apnea (OSA) patients by raising the arousal threshold to airway occlusion.
Area of Science:
- Sleep Medicine
- Pharmacology
Background:
- Obstructive sleep apnea (OSA) is a common sleep disorder characterized by repeated episodes of airway collapse during sleep.
- Understanding the effects of medications on OSA pathophysiology is crucial for patient management.
Purpose of the Study:
- To evaluate the impact of a low dose of triazolam (0.25 mg) on apnea duration and arousal response to airway occlusion in severe OSA patients.
Main Methods:
- A randomized, double-blind, crossover study involving 12 male subjects with severe OSA.
- Subjects received either triazolam (0.25 mg) or placebo before bedtime on two separate nights.
- Apnea duration, oxygen saturation, and esophageal pressure during non-rapid-eye-movement (NREM) sleep were monitored.
Main Results:
- Triazolam slightly increased apnea/hypopnea duration (26.8 vs. 23.8 s) and lowered mean nadir oxygen saturation (80.1% vs. 84.2%) during NREM sleep.
- Higher esophageal pressure deflections were observed before apnea termination with triazolam.
- The rate of inspiratory effort increase during obstructive events was not reduced by triazolam.
Conclusions:
- Triazolam (0.25 mg) elevates the arousal threshold to airway occlusion in severe OSA patients.
- This effect leads to modest increases in event duration and greater oxygen desaturation.
- The findings suggest a limited benefit and potential risks of low-dose triazolam in this patient population.